{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:58:03Z","timestamp":1790765883776,"version":"4.1.0"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Leptomeningeal metastasis (LM) is a devastating form of central nervous system (CNS) dissemination in lung cancer, particularly non-small cell lung cancer (NSCLC). Current treatment frameworks emphasize CNS drug penetration, oncogenic driver evolution, and intrathecal therapy. Emerging evidence supports viewing the cerebrospinal fluid (CSF) compartment as an active tumor-immune space, but the field remains early, with limited lung cancer-specific mechanistic and single-cell datasets. Lung cancer cells in CSF appear to adapt to low protein content, limited nutrients, fluid shear, weak matrix support, and compartmental immune surveillance. Meanwhile, available CSF studies suggest immune states marked by exhausted T cells, regulatory lymphoid programs, suppressive myeloid remodeling, cytokine dysregulation, and tumor-supportive signaling. This review summarizes the CSF metastatic niche, tumor adaptation, immune-cell states, tumor-immune crosstalk, therapy-associated remodeling, and CSF multi-omics in lung cancer LM. We propose that CSF-guided profiling may help generate immune-state classifications and inform future targeted, intrathecal, immune, or combination strategies, while requiring prospective validation before routine treatment guidance.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1959655","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:09:28Z","timestamp":1790762968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The cerebrospinal fluid immune microenvironment in lung cancer leptomeningeal metastasis: cellular ecosystems and therapeutic possibilities"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuanzheng","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Second Norman Bethune Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-025-00828-7","article-title":"Leptomeningeal metastases in non-small cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae103","article-title":"Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions","volume":"26","author":"Wilcox","year":"2024","journal-title":"Neuro Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2025.102.39","article-title":"Chinese expert consensus on clinical management of oncogene addicted non-small cell lung cancer with leptomeningeal metastasis (2026 edition)","year":"2026","journal-title":"Zhongguo fei ai za zhi = Chin J Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06416-2","article-title":"Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review","author":"Ding","year":"2026","journal-title":"J Cancer Res Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251403396","article-title":"Treatment options for EGFR mutation-positive NSCLC patients with leptomeningeal metastases after third-generation TKI resistance: a retrospective real-world study","author":"Yun","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000552332","article-title":"Decision-making in intrathecal therapy for leptomeningeal disease","author":"Weindler","year":"2026","journal-title":"Oncology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.25259\/SNI_884_2025","article-title":"Different methods of cerebrospinal fluid diversion in patients with leptomeningeal metastasis: A systematic review and meta-analysis","author":"Pangaribuan","year":"2025","journal-title":"Surg Neurol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18132169","article-title":"Leptomeningeal metastasis in non-small-cell lung cancer with actionable genomic alterations: pathogenesis, diagnosis, and emerging therapeutic strategies","author":"Lim","year":"2026","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2026.1737679","article-title":"Treatment decision-making for leptomeningeal metastasis after TKI resistance in EGFR-mutant lung cancer: a comprehensive review on staging, resistance patterns, and multimodal interventions","volume":"17","author":"Song","year":"2026","journal-title":"Front Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5218","article-title":"Targeting CNS metastases in non-small cell lung cancer with evolving approaches using molecular markers: A review","author":"Malhotra","year":"2025","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213686","article-title":"Diagnostics and screening in breast cancer with brain and leptomeningeal metastasis: A review of the literature","author":"Cohen-Nowak","year":"2024","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-15503-z","article-title":"A survival prediction model for leptomeningeal metastasis patients with non-small cell lung cancer based on deep learning","author":"Jin","year":"2025","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1101\/2024.01.03.23300646","article-title":"Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis","volume":"8","author":"Azad","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101113","article-title":"Clinical utility and predictive value of cerebrospinal fluid cell-free DNA profiling in non-small cell lung cancer patients with leptomeningeal metastasis","volume":"57","author":"Liang","year":"2025","journal-title":"Neoplasia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41568-024-00700-y","article-title":"The path to leptomeningeal metastasis","volume":"24","author":"Remsik","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/neuonc\/nox036.016","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.885","article-title":"Single-cell RNA sequencing reveals the characteristics of cerebrospinal fluid tumour environment in breast cancer and lung cancer leptomeningeal metastases","volume":"12","author":"Ruan","year":"2022","journal-title":"Clin Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00858-2","article-title":"Dura immunity configures leptomeningeal metastasis immunosuppression for cerebrospinal fluid barrier invasion","volume":"5","author":"Zhao","year":"2024","journal-title":"Nat Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41421-025-00828-7","article-title":"Immunological and pathological characteristics of brain parenchymal and leptomeningeal metastases from non-small cell lung cancer","volume":"11","author":"Zhou","year":"2025","journal-title":"Cell Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114613","article-title":"Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC","volume":"43","author":"Li","year":"2024","journal-title":"Cell Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013588","article-title":"CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis","volume":"14","author":"Wang","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-024-10235-1","article-title":"Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities","volume":"43","author":"Smith","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223746","article-title":"Multi-omic characterization of single cells and cell-free components detected in the cerebrospinal fluid of patients with leptomeningeal disease","volume":"16","author":"Shishido","year":"2024","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20142290","article-title":"A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules","volume":"212","author":"Aspelund","year":"2015","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1146\/annurev-immunol-102319-103410","article-title":"Meningeal immunity and its function in maintenance of the central nervous system in health and disease","volume":"38","author":"Alves de Lima","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2021.1903390","article-title":"Choroid plexus and CSF: an updated review","volume":"36","author":"Hutton","year":"2022","journal-title":"Br J Neurosurg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2021.07.002","article-title":"Macrophages on the margin: choroid plexus immune responses","volume":"44","author":"Cui","year":"2021","journal-title":"Trends Neurosci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.246","article-title":"Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single-cell transcriptome analysis","volume":"10","author":"Ruan","year":"2020","journal-title":"Clin Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102651","article-title":"Integrative CSF profiling identifies disease-specific immune responses in leptomeningeal disease","volume":"7","author":"Nieto","year":"2026","journal-title":"Cell Rep Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdag058","article-title":"The immune profile of cerebrospinal fluid across brain malignancies","volume":"8","author":"Kim","year":"2026","journal-title":"Neuro-Oncol Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04616-3","article-title":"Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers","author":"Nakagawa","year":"2024","journal-title":"J Neuro-Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.14791\/btrt.2026.0001","article-title":"Fate of brain metastasis with cerebrospinal fluid space invasion based on MRI findings: clinical features and factors affecting progression to overt leptomeningeal metastasis","author":"Hong","year":"2026","journal-title":"Brain Tumor Res Treat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-05220-9","article-title":"Development and validation of a predictive nomogram for leptomeningeal metastasis risk in NSCLC brain metastases: role of tumor location, driver mutations, and stereotactic radiosurgery","author":"Bashir","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz208","article-title":"A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small cell lung cancer","author":"Nevel","year":"2020","journal-title":"Neuro Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-026-04370-8","article-title":"Machine learning-based prognostic model and single-cell transcriptomic integration for identifying brain metastasis-associated malignant subpopulations and potential therapeutic targets in lung adenocarcinoma","author":"Pang","year":"2026","journal-title":"Cancer Cell Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-74782-7","article-title":"Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T-cell responses and promoting tertiary lymphoid structure formation","author":"Hosoya","year":"2026","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-026-08447-w","article-title":"Single-cell and spatial transcriptomes reveal oligodendrocyte remodeling fatty acid metabolism microenvironment of lung cancer brain metastases","author":"Yang","year":"2026","journal-title":"J Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-026-05341-1","article-title":"Single-cell data analysis of lung cancer brain metastasis reveals SEC61G serves as a potential risk indicator","author":"Li","year":"2026","journal-title":"Discov Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27093997","article-title":"Coordinated multicellular immune programs and drug targets revealed by single-cell analysis in driver-mutated NSCLC","author":"Yang","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101606","article-title":"Spatial transcriptomics analysis identifies a tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease","author":"Alhaddad","year":"2024","journal-title":"Cell Rep Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/s12967-025-06671-4","article-title":"Multimodal evaluation of cerebrospinal fluid from breast cancer leptomeningeal metastases using circulating tumor cell detection, single-cell sequencing, and proteomics","volume":"23","author":"Rahbarlayegh","year":"2025","journal-title":"J Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115377","article-title":"Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors","volume":"219","author":"van Kessel","year":"2025","journal-title":"Eur J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.140","article-title":"The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study","volume":"37","author":"Zheng","year":"2026","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2020.07.003","article-title":"EMT, MET, plasticity, and tumor metastasis","volume":"30","author":"Bakir","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2024-2047","article-title":"Efficacy evaluation of tyrosine kinase inhibitors for advanced non-small cell lung cancer patients with leptomeningeal metastasis","author":"Wang","year":"2025","journal-title":"J Thorac Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100332","article-title":"Crossing barriers with CSF-based sequencing for leptomeningeal disease in EGFR mutant NSCLC","author":"Chugh","year":"2025","journal-title":"J Liquid Biopsy"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100450","article-title":"Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare of EGFR-mutant disease after switch to selpercatinib for acquired RET fusion","author":"Kunimasa","year":"2025","journal-title":"J Liquid Biopsy"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108593","article-title":"Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors","author":"Xie","year":"2025","journal-title":"Lung Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100704","article-title":"Combination of cytologic findings and circulating tumor DNA from cerebrospinal fluid revealed SCLC transformation in patients with leptomeningeal metastases of lung adenocarcinoma","author":"Lin","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae138","article-title":"Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib resistance analysis-leptomeningeal metastases study","author":"van der Wel","year":"2024","journal-title":"Neuro Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04716-0","article-title":"High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer","author":"Yu","year":"2024","journal-title":"J Neuro-Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.2640","article-title":"Lazertinib in EGFR-variant non-small cell lung cancer with CNS failure to prior EGFR tyrosine kinase inhibitors: A nonrandomized controlled trial","author":"Hong","year":"2024","journal-title":"JAMA Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.2023.2191069","article-title":"Untargeted metabolomics analysis of cerebrospinal fluid in patients with leptomeningeal metastases from non-small cell lung cancer","author":"Li","year":"2024","journal-title":"Biotechnol Genet Eng Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz2193","article-title":"Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis","author":"Chi","year":"2020","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41698-026-01379-0","article-title":"Cellular landscape and diagnostic value of TROP2 in cerebrospinal fluid of lung adenocarcinoma leptomeningeal metastases","volume":"10","author":"Wang","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-aw-1247","article-title":"Pathophysiology and treatment of leptomeningeal metastases in lung cancer","volume":"15","author":"Hida","year":"2026","journal-title":"Transl Lung Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1177\/11795549261466835","article-title":"Integrative analysis of clinical features and cerebrospinal fluid immune microenvironment in leptomeningeal metastasis from non-small-cell lung cancer patients","volume":"20","author":"Chen","year":"2026","journal-title":"Clin Med Insights Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.molmed.2025.10.008","article-title":"Emerging innovative treatments for leptomeningeal metastatic tumors","volume":"32","author":"Kanaya","year":"2026","journal-title":"Trends Mol Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.787080","article-title":"Immunotherapy in NSCLC patients with brain and leptomeningeal metastases","volume":"12","author":"Pierret","year":"2022","journal-title":"Front Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-1088","article-title":"Long-term survival in a patient with leptomeningeal metastases from non-small cell lung cancer treated with stereotactic radiotherapy (SRT), programmed cell death protein 1 (PD-1) inhibitor, and granulocyte-macrophage colony-stimulating factor (GM-CSF): a case report","author":"Huan","year":"2025","journal-title":"Trans Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000001088","article-title":"Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study","author":"Aboelatta","year":"2026","journal-title":"Melanoma Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061884","article-title":"Leptomeningeal disease (LMD) in patients with melanoma metastases","author":"Khaled","year":"2023","journal-title":"Cancers"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09012-z","article-title":"Interferon-gamma orchestrates leptomeningeal anti-tumour response","author":"Remsik","year":"2025","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.5493\/wjem.v16.i1.117938","article-title":"Melanoma leptomeningeal disease: Advances in diagnosis and emerging therapeutic strategies","author":"Middleton","year":"2026","journal-title":"World J Exp Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03094-2","article-title":"Elucidating the association between TLR-4 expression and the clinical course of glioblastoma leptomeningeal disease","author":"Lu","year":"2025","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04788-y","article-title":"Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression","author":"Rogawski","year":"2024","journal-title":"J Neuro-Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108933","article-title":"Treatment strategies for leptomeningeal disease in patients with breast cancer","author":"Spanehl","year":"2025","journal-title":"Pharmacol Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105156","article-title":"Recent advances in systemic treatment for HER2-negative breast cancer with brain metastases","author":"Hao","year":"2026","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.04.005","article-title":"Clinical outcomes of patients with non-small cell lung cancer leptomeningeal disease following receipt of EGFR-targeted therapy, immune-checkpoint blockade, intrathecal chemotherapy, or radiation therapy alone","volume":"25","author":"Mills","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf123.030","article-title":"Phase IB study of avelumab and whole brain radiotherapy in patients with leptomeningeal disease from solid tumors: Results and molecular analyses","volume":"27","author":"Pina","year":"2025","journal-title":"Neuro Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2026.112076","article-title":"Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies","volume":"138","author":"Fisher","year":"2026","journal-title":"J Clin Neurosci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-15915-5","article-title":"Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study","author":"Wang","year":"2026","journal-title":"BMC Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108586","article-title":"Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma","volume":"205","author":"Ruan","year":"2025","journal-title":"Lung Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-026-01185-4","article-title":"Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1\/NOA-26 phase 1 trial","author":"Tabatabai","year":"2026","journal-title":"Nat Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: A prospective real-world study","volume":"20","author":"Chen","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.107743","article-title":"Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)","volume":"11","author":"Chen","year":"2026","journal-title":"ESMO Open"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2025.101.24","article-title":"Efficacy and safety of high-dose furmonertinib plus intrathecal pemetrexed for EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis","author":"Chen","year":"2025","journal-title":"Zhongguo fei ai za zhi = Chin J Lung Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e40703","article-title":"Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small cell lung cancer with leptomeningeal metastases","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.18063","article-title":"Leptomeningeal metastasis in patients with EGFR-positive NSCLC: A propensity-matched retrospective study of patients with EGFR-negative NSCLC","author":"Satoh","year":"2026","journal-title":"Anticancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-025-06490-y","article-title":"Comparative analysis of the lumboperitoneal shunt versus ventriculoperitoneal shunt for leptomeningeal metastasis-associated hydrocephalus in non-small cell lung cancer","author":"Kim","year":"2025","journal-title":"Acta Neurochirurgica"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2174\/0929867330666230508142657","article-title":"A review on the efficacy and safety of intrathecal administration of novel medications for leptomeningeal metastases in solid cancers","author":"Jafari","year":"2024","journal-title":"Curr Med Chem"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108809","article-title":"Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study","volume":"208","author":"Jung","year":"2025","journal-title":"Lung Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1627170","article-title":"Savolitinib in brain and leptomeningeal metastases from non-small cell lung cancer: a case report","volume":"16","author":"Qi","year":"2026","journal-title":"Front Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35460","article-title":"Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study","author":"Xie","year":"2025","journal-title":"Int J Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1720422","article-title":"Correction: Case report: A case report and literature review on the efficacy of high-dose aumolertinib combined intrathecal pemetrexed by Ommaya reservoir for EGFR-mutated NSCLC with leptomeningeal metastasis as the initial symptoms","volume":"15","author":"Zhong","year":"2025","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001748","article-title":"Overcoming refractory leptomeningeal metastasis in nonsmall cell lung cancer with intrathecal pemetrexed and osimertinib: a case report","author":"Xue","year":"2025","journal-title":"Anti-cancer Drugs"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1581754","article-title":"Integration of continuous lumbar drainage and third-generation EGFR-TKI in managing leptomeningeal metastasis-induced life-threatening intracranial hypertension: a case report","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1788293","article-title":"Intrathecal chemotherapy for leptomeningeal metastasis of non-small cell lung cancer: a systematic review","volume":"17","author":"Wang","year":"2026","journal-title":"Front Pharmacol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1746953","article-title":"Advances in Ommaya reservoir-based intrathecal therapy for leptomeningeal metastasis from non-small cell lung cancer: a systematic review","volume":"16","author":"Jiang","year":"2026","journal-title":"Front Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2026-116187","article-title":"Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial","volume":"16","author":"Kuang","year":"2026","journal-title":"BMJ Open"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2026.108918","article-title":"Combined intrathecal therapy via Ommaya reservoir and whole-brain radiotherapy improves survival in EGFR-mutant NSCLC patients with leptomeningeal metastases: a real-world cohort study","volume":"210","author":"Li","year":"2026","journal-title":"Lung Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-026-03407-z","article-title":"Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes","author":"Wang","year":"2026","journal-title":"Br J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-26-0738","article-title":"Intrathecal allogeneic B7-H3-targeted CAR gamma delta T cells for leptomeningeal metastasis from solid tumors: Safety, efficacy, and immunological dynamics in a phase 1 trial","author":"Ma","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.70082","article-title":"A new era in leptomeningeal disease (LMD): Recent advancements in immunocellular and radiation therapies in melanoma LMD, what has been done and future directions","author":"Patra","year":"2026","journal-title":"Pigment Cell Melanoma Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf006","article-title":"Engineered allogeneic stem cells orchestrate T lymphocyte-driven immunotherapy in immunosuppressive leptomeningeal brain metastasis","volume":"117","author":"Kanaya","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1186\/s12967-024-05794-4","article-title":"Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis","volume":"22","author":"Zhao","year":"2024","journal-title":"J Transl Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100533","article-title":"A structured evaluation of cryopreservation in generating single-cell transcriptomes from cerebrospinal fluid","volume":"3","author":"Touil","year":"2023","journal-title":"Cell Rep Methods"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1186\/s12885-025-14583-1","article-title":"Cerebrospinal fluid circulating tumor DNA (ctDNA) as a biomarker for CNS metastases in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis comparing CSF ctDNA and traditional methods","volume":"25","author":"Olayode","year":"2025","journal-title":"BMC Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-026-05520-8","article-title":"Cerebrospinal fluid ctDNA as a prognostic and disease-activity biomarker in leptomeningeal metastases: systematic review, meta-analysis, and implications for CSF-guided care","author":"Sankar","year":"2026","journal-title":"J Neuro-Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1060","article-title":"Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors","volume":"14","author":"Stutheit-Zhao","year":"2024","journal-title":"Cancer Discov"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2396","article-title":"A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan","volume":"31","author":"Nakamura","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2024.102.16","article-title":"Advances in clinical application of cerebrospinal fluid circulating tumor DNA in leptomeningeal metastasis of non-small cell lung cancer","author":"Li","year":"2024","journal-title":"Zhongguo fei ai za zhi = Chin J Lung Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-026-02350-7","article-title":"Low-input CSF cfDNA shallow whole-genome sequencing for CNV-based diagnosis and monitoring of leptomeningeal metastasis in lung cancer","author":"Guan","year":"2026","journal-title":"Acta Neuropathol Commun"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad150","article-title":"Keeping a track on leptomeningeal disease in non-small cell lung cancer: a single-institution experience with CNSideTM","author":"Puri","year":"2024","journal-title":"Neuro-Oncol Adv"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00373","article-title":"Clinical utility of a circulating tumor cell-based cerebrospinal fluid assay in the diagnosis and molecular analysis of leptomeningeal disease in patients with advanced non-small cell lung cancer","author":"Malhotra","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1409383","article-title":"Applications of cerebrospinal fluid circulating tumor cells and circulating tumor-derived DNA in diagnosis, prognosis, and personalized treatment of CNS metastases","volume":"14","author":"Pentsova","year":"2024","journal-title":"Front Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101881","article-title":"Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors","author":"Diaz","year":"2024","journal-title":"Transl Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050825","article-title":"Longitudinal CSF tumor cell enumeration and mutational analysis as a driver for leptomeningeal disease management","author":"Tripathy","year":"2025","journal-title":"Cancers"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04471-8","article-title":"Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases","author":"Bai","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.902664","article-title":"EGFR amplification is a putative resistance mechanism for NSCLC-LM patients with TKI therapy and is associated with poor outcome","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70245","article-title":"Tumor marker test in cerebrospinal fluid for leptomeningeal metastasis diagnosis and response assessment in non-small-cell lung cancer","author":"Huang","year":"2025","journal-title":"Eur J Neurol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1716168","article-title":"Detection of circulating hybrid cells and circulating tumor cells in cerebrospinal fluid for leptomeningeal metastasis diagnosis and therapeutic prediction","volume":"13","author":"Liu","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201601394","article-title":"Affinity versus label-free isolation of circulating tumor cells: Who wins","volume":"12","author":"Murlidhar","year":"2016","journal-title":"Small"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-026-10420-2","article-title":"Systematic review of extracellular vesicle-based liquid biopsy for leptomeningeal metastasis: current evidence and future directions","author":"Babel","year":"2026","journal-title":"Clin Exp Metastasis"},{"key":"B118","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3892\/ol.2026.15621","article-title":"Advances in cerebrospinal fluid biomarkers for the diagnosis, treatment and monitoring of leptomeningeal metastases (review)","volume":"32","author":"Li","year":"2026","journal-title":"Oncol Lett"},{"key":"B119","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41698-025-01218-8","article-title":"Serial monitoring of cerebrospinal fluid in patients with leptomeningeal metastases in lung cancer via the Ommaya reservoir as a predictive indicator of therapeutic efficacy and clinical prognosis","volume":"9","author":"Fang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12014-026-09604-5","article-title":"The effect of preanalytical factors on cerebrospinal fluid and plasma proteomics: a systematic experimental study","volume":"23","author":"Tatsumi","year":"2026","journal-title":"Clin Proteomics"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-026-03923-2","article-title":"Efficacy of osimertinib combined with anti-VEGF therapy ramucirumab in managing leptomeningeal metastasis in EGFR-mutant NSCLC: a case report and literature review","author":"Tsai","year":"2026","journal-title":"J Cardiothoracic Surg"},{"key":"B122","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-025-01412-y","article-title":"Leptomeningeal disease: Current approaches and future directions","volume":"25","author":"Sener","year":"2025","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1959655\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:09:33Z","timestamp":1790762973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1959655\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":122,"alternative-id":["10.3389\/fimmu.2026.1959655"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1959655","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1959655"}}